A novel oral amphotericin B (MAT2203) developed by Matinas BioPharma for treatment of invasive mucormycosis (IM) and other deadly invasive fungal infections, has demonstrated encouraging results in a ...

Cresemba for injection is indicated for children 1 year of age and older; the capsule formulation is approved for patients 6 years of age and older weighing at least 16kg. The Food and Drug ...

(Reuters) - A panel of experts on Thursday voted to recommend that U.S. health regulators approve Astellas Pharma Inc's drug for the treatment of rare, often fatal invasive fungal infections that can ...

NORTHBROOK, Ill., March 11, 2024 /PRNewswire/ -- Astellas Pharma US, Inc. (TSE: 4503, President: Mark Reisenauer, "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has ...

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of isavuconazole (Cresemba, Basilea Medical Ltd) to treat adults with invasive ...

Astellas Pharma has received the Food and Drug Administration’s permission for Cresemba (isavuconazonium sulfate), an azole antifungal drug, for the treatment of invasive aspergillosis and invasive ...

Immunotherapy. 2012;4(1):107-120. Despite use of antifungal agents with in vitro activity against these molds, outcomes are poor in patients with persistent neutropenia or other immune deficits.

Researchers from Scynexis Inc. have recently presented details on the preclinical characterization of SCY-247, a second-generation triterpenoid with glucan synthase inhibitor activity and intended to ...

A new lateral-flow test could one day save lives across the world through early detection of a deadly fungal disease that dramatically spiked during the COVID-19 pandemic.

Albumin is the most common protein in the blood, a vital molecule produced by the liver that helps maintain fluid balance and transports proteins and hormones. It also plays a key role in fighting off ...